Targeted Agents in Patients with Progressive Glioblastoma-A Systematic Meta-analysis of Randomized Clinical Trials

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Dec 2

PMID 39618405

Authors

Franziska Maria Ippen

Angelika Scherm

Tobias Kessler

Peter Hau

Sarina Agkatsev

Hansjorg Baurecht

Wolfgang Wick

Helge Knuttel

Michael F Leitzmann

Corinna Seliger-Behme

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma (GB) is the most common malignant primary brain tumor in adults and is associated with a poor prognosis. Current treatment guidelines outline the standard of care for patients with newly diagnosed GB; however, there is currently no well-established consensus for the treatment of progressive GB. With this systematic meta-analysis of recently published randomized controlled trials (RCTs), we aim to establish evidence on targeted agents in the treatment of patients with progressive GB.

Material And Methods: We conducted searches across the Cochrane Library, Pubmed, MEDLINE (Ovid), ClinicalTrials.gov, WHO's International Clinical Trials Registry Platform and Google Scholar, encompassing the time span from 1954 to 2022, aiming to identify RCTs evaluating targeted therapies in patients with progressive GB. In order to perform a random-effects meta-analysis, we extracted hazard ratios (HRs) of overall survival (OS) and progression-free survival (PFS).

Results: We included 16 RCTs (n = 3025 patients) in the systematic meta-analysis. Formally, regorafenib (RR 0.50; 95% CI 0.33-0.75), Depatux-M + TMZ (RR 0.66; 95% CI 0.47-0.93) and rindopepimut + bevacizumab (RR 0.53; 95% CI 0.32-0.88) were associated with an improved OS compared to the control arm. The combination of bevacizumab + CCNU (RR = 0.49; 95% CI 0.35-0.69) and regorafenib (RR 0.65; 95% CI 0.44-0.95) were formally associated with improved PFS.

Conclusions: The aim of this systematic meta-analysis was to establish evidence for the use of targeted therapies in progressive GB. While some studies demonstrated benefits for OS and/or PFS, those results have to be interpreted with caution as most studies had major methodological weaknesses, including potential differences in sample size, trial design, or the initial distribution of prognostic factors.

References

van den Bent M, Eoli M, Sepulveda J, Smits M, Walenkamp A, Frenel J . INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2019; 22(5):684-693. PMC: 7229258. DOI: 10.1093/neuonc/noz222. View

Scherm A, Ippen F, Hau P, Baurecht H, Wick W, Gempt J . Targeted therapies in patients with newly diagnosed glioblastoma-A systematic meta-analysis of randomized clinical trials. Int J Cancer. 2023; 152(11):2373-2382. DOI: 10.1002/ijc.34433. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Bramer W, Giustini D, de Jonge G, Holland L, Bekhuis T . De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016; 104(3):240-3. PMC: 4915647. DOI: 10.3163/1536-5050.104.3.014. View

Kurz S, Wen P . Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?. Curr Treat Options Neurol. 2018; 20(5):14. DOI: 10.1007/s11940-018-0499-0. View

Reardon D, Nabors L, Mason W, Perry J, Shapiro W, Kavan P . Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2014; 17(3):430-9. PMC: 4483093. DOI: 10.1093/neuonc/nou160. View

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Brandes A, Gil-Gil M, Saran F, Carpentier A, Nowak A, Mason W . A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. Oncologist. 2018; 24(4):521-528. PMC: 6459244. DOI: 10.1634/theoncologist.2018-0290. View

10.

Lee E, Zhang P, Wen P, Gerstner E, Reardon D, Aldape K . NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020; 126(12):2821-2828. PMC: 7245544. DOI: 10.1002/cncr.32811. View

11.

Seystahl K, Wick W, Weller M . Therapeutic options in recurrent glioblastoma--An update. Crit Rev Oncol Hematol. 2016; 99:389-408. DOI: 10.1016/j.critrevonc.2016.01.018. View

12.

Lassman A, Pugh S, Wang T, Aldape K, Gan H, Preusser M . Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol. 2022; 25(2):339-350. PMC: 9925712. DOI: 10.1093/neuonc/noac173. View

13.

Wick W, Puduvalli V, Chamberlain M, van den Bent M, Carpentier A, Cher L . Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010; 28(7):1168-74. PMC: 2834468. DOI: 10.1200/JCO.2009.23.2595. View

14.

Lombardi G, De Salvo G, Brandes A, Eoli M, Ruda R, Faedi M . Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2018; 20(1):110-119. DOI: 10.1016/S1470-2045(18)30675-2. View

15.

Mar N, Desjardins A, Vredenburgh J . CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations. Clin Cancer Res. 2015; 21(19):4248-50. DOI: 10.1158/1078-0432.CCR-15-1381. View

16.

Wen P, Junck L . Bevacizumab for glioblastoma: what can we learn from patterns of progression?. Neurology. 2014; 82(19):1670-1. DOI: 10.1212/WNL.0000000000000421. View

17.

Reardon D, Brandes A, Omuro A, Mulholland P, Lim M, Wick A . Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(7):1003-1010. PMC: 7243167. DOI: 10.1001/jamaoncol.2020.1024. View

18.

Eichler H, Sweeney F . The evolution of clinical trials: Can we address the challenges of the future?. Clin Trials. 2018; 15(1_suppl):27-32. DOI: 10.1177/1740774518755058. View

19.

McGowan J, Sampson M, Salzwedel D, Cogo E, Foerster V, Lefebvre C . PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016; 75:40-6. DOI: 10.1016/j.jclinepi.2016.01.021. View

20.

Galanis E, Anderson S, Twohy E, Carrero X, Dixon J, Tran D . A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019; 125(21):3790-3800. PMC: 6788934. DOI: 10.1002/cncr.32340. View